SynthesisCell and tissue research2026
Artificial intelligence for stromal cell quality assessment: A systematic review of human mesenchymal stromal cell properties and viability.
Synthesis in Cell and tissue research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Reliable assessment of mesenchymal stromal cell (MSC) viability and stem cell-associated properties is essential for ensuring the consistency, safety, and therapeutic potential of MSC cultures before clinical use. However, incomplete understanding of the mechanisms underlying MSC therapeutic effects remains a major barrier to clinical translation and to establishing reliable, standardised quality attributes. Artificial intelligence (AI) may enable automated assessment of these properties, but the performance and clinical relevance of AI-based approaches have not been systematically evaluated. This systematic review evaluated the accuracy and clinical utility of AI for assessing viability and stem cell-associated properties in human MSC cultures. Following PRISMA guidelines, we searched five electronic databases (Cochrane, Scopus, PubMed, EMBASE, and MEDLINE) for eligible studies reporting quantitative AI-based assessments of human MSC cultures. Two reviewers independently screened studies, extracted data, and assessed risk of bias using PROBAST. The review protocol was prospectively registered with PROSPERO (CRD420256393235). Of 3,872 records identified, 18 studies met the inclusion criteria. Supervised AI models, particularly convolutional neural networks, were most used. Across included studies, reported performance metrics varied substantially because of differences in AI models, imaging modalities, datasets, and outcome definitions. Considerable heterogeneity in AI model architectures, imaging modalities, outcome definitions, and reporting metrics limited direct comparison across studies. Overall, available evidence suggests that AI can assess key MSC quality attributes and may support more objective, scalable, and standardised quality-control workflows. However, broader validation, standardised reporting, external testing, and evaluation across a wider range of MSC characteristics are required before routine clinical implementation can be recommended.
Indexed as
Identifiers
42878873What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.